Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot cervical cancer without a biopsy

NCT ID NCT07796672

Diagnosis Sponsor: Queensland Centre for Gynaecological Cancer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This trial tests whether a simple blood test can help detect and monitor cervical cancer. Researchers will analyze tiny DNA fragments and particles in the blood, called cell-free DNA and extracellular vesicles, to see if they act as early warning signs. The study involves 100 women with cervical cancer who will give blood samples before, during, and after treatment. If these biomarkers prove reliable, the test could offer a less invasive way to track the disease and guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sample collection and analysis of cell-free DNA (cfDNA) and extracellular vesicles (EVs)
What this could lead to
If successful, this could lead to a simple blood test for earlier detection, real-time treatment monitoring, and prediction of recurrence in cervical cancer, reducing the need for invasive biopsies.
What could go wrong
This is an early feasibility study with 100 participants, so the findings may not apply broadly. The biomarkers may not prove reliable, and the analysis is complex, with no guarantee of clinical utility yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2032

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

100 patients with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b).

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females, over 18 years, with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b) * Undergo intensive primary surgical treatment, radiotherapy (RT) or chemoradiotherapy (CRT). * Signed written informed consent Exclusion Criteria: * Unable to provide informed consent * Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator) * Prior malignancies \<5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical adenocarcinoma cervical squamous cell carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical adenocarcinoma Cervical squamous cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Brisbane and Women's Hospital

    RECRUITING

    Brisbane, Queensland, 4029, Australia

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.